Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- NCT00104130
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
- Detailed Description
This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 53
- At least 18 years of age.
- Metastatic disease.
- One previous treatment including docetaxel (Taxotere).
- At least 3 weeks since last surgery/radiation/chemotherapy
- ECOG Performance Status of 0, 1 or 2
- Active brain metastases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method prostate cancer prostate-specific antigen (PSA) response
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Georgia Cancer Specialists
🇺🇸Tucker, Georgia, United States
Kaiser Permanente NW Oncology Clinic
🇺🇸Portland, Oregon, United States
Kaiser Permanente Medical Center
🇺🇸Vallejo, California, United States
University of Maryland Medical System
🇺🇸Baltimore, Maryland, United States
Washington University School of Medicine
🇺🇸St. Louis, Missouri, United States
University of Washington
🇺🇸Seattle, Washington, United States
The Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States